Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteersKIRCHHEINERA, Julia; MEINEKE, Ingolf; MÜLLER, Gunnar et al.Pharmacogenetics (London). 2002, Vol 12, Num 7, pp 571-580, issn 0960-314X, 10 p.Article

Adherence to and dosing of β-hydroxy-β-methylglutaryl coenzyme a reductase inhibitors in the general population differs according to apolipoprotein E-genotypesMAITLAND-VAN DER ZEE, Anke-Hilse; STRICKER, Bruno H. Ch; KLUNGEL, Olaf H et al.Pharmacogenetics (London). 2003, Vol 13, Num 4, pp 219-223, issn 0960-314X, 5 p.Article

Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT studyLYNCH, Amy I; ECKFELDT, John H; DAVIS, Barry R et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 5, pp 355-366, issn 1744-6872, 12 p.Article

Pharmacosynthetics: Reimagining the pharmacogenetic approachFARRELL, Martilias S; ROTH, Bryan L.Brain research. 2013, Vol 1511, pp 6-20, issn 0006-8993, 15 p.Article

A GENOMIC ROADMAP TO BETTER DRUGSGUOCHUN LIAO; XUN ZHANG; CLARK, David J et al.Drug metabolism reviews (Softcover ed.). 2008, Vol 40, Num 2, pp 225-239, issn 0360-2532, 15 p.Article

A pharmacogenetic study of vorinostat glucuronidationKANG, Soonmo Peter; RAMIREZ, Jacqueline; HOUSE, Larry et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 10, pp 638-641, issn 1744-6872, 4 p.Article

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human liversYODER GRABER, Andrea L; RAMIREZ, Jacqueline; INNOCENTI, Federico et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 8, pp 619-627, issn 1744-6872, 9 p.Article

Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibeWANG, J; WILLIAMS, C. M; HEGELE, R. A et al.Clinical genetics. 2005, Vol 67, Num 2, pp 175-177, issn 0009-9163, 3 p.Article

Bioethics and the Reinforcement of Socio-technical Expectations = La bioéthique et le renforcement des attentes socio-techniquesHEDGECOE, Adam.Social studies of science. 2010, Vol 40, Num 2, pp 163-186, issn 0306-3127, 24 p.Article

Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)URBAN, Thomas J; CHEN YANG; CARLSON, Elaine J et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 9, pp 773-782, issn 1744-6872, 10 p.Article

Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influenceSWAN, Gary E; BENOWITZ, Neal L; LESSOV, Christina N et al.Pharmacogenetics (London). 2005, Vol 15, Num 2, pp 115-125, issn 0960-314X, 11 p.Article

Cancer pharmacogeneticsMARSH, S; MCLEOD, H. L.British journal of cancer. 2004, Vol 90, Num 1, pp 8-11, issn 0007-0920, 4 p.Article

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in manKUPFER, A; PREISIG, R.European journal of clinical pharmacology. 1984, Vol 26, Num 6, pp 753-759, issn 0031-6970Article

Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatmentO'GARA, Colin; STAPLETON, John; SUTHERLAND, Gay et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 1, pp 61-67, issn 1744-6872, 7 p.Article

Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2OWEN, Ryan P; GRAY, Jennifer H; TAYLOR, Travis R et al.Pharmacogenetics (London). 2005, Vol 15, Num 2, pp 83-90, issn 0960-314X, 8 p.Article

Pharmacogenetics in the treatment of depression: pharmacodynamic studiesSERRETTI, Alessandro; ARTIOLI, Paola; QUARTESAN, Roberto et al.Pharmacogenetics (London). 2005, Vol 15, Num 2, pp 61-67, issn 0960-314X, 7 p.Article

Detecting epistatic interactions contributing to quantitative traitsCULVERHOUSE, Robert; KLEIN, Tsvika; SHANNON, William et al.Genetic epidemiology. 2004, Vol 27, Num 2, pp 141-152, issn 0741-0395, 12 p.Article

An omics view of drug developmentALTMAN, Russ B; RUBIN, Daniel L; KLEIN, Teri E et al.Drug development research. 2004, Vol 62, Num 2, pp 81-85, issn 0272-4391, 5 p.Article

Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and PitfallsFALCONE, Mary; SMITH, Ryan M; CHENOWETH, Meghan J et al.Neuropsychopharmacology (New York, NY). 2013, Vol 38, Num 12, pp 2327-2337, issn 0893-133X, 11 p.Article

Personalized Cardiovascular Medicine and Drug Development: Time for a New ParadigmLOSCALZO, Joseph.Circulation (New York, N.Y.). 2012, Vol 125, Num 4, pp 638-645, issn 0009-7322, 8 p.Article

Current progress in pharmacogeneticsBLAKEY, John D; HALL, Ian P.British journal of clinical pharmacology. 2011, Vol 71, Num 6, pp 824-831, issn 0306-5251, 8 p.Article

Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacyBURCZYNSKI, M. E.Toxicology letters. 2009, Vol 186, Num 1, pp 18-21, issn 0378-4274, 4 p.Article

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideKALLIOKOSKI, Annikka; BACKMAN, Janne T; NEUVONEN, Pertti J et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 937-942, issn 1744-6872, 6 p.Article

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)FUJITA, Tomoe; BROWN, Chaline; CHEN, Chung-Wen et al.Pharmacogenetics (London). 2005, Vol 15, Num 4, pp 201-209, issn 0960-314X, 9 p.Article

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic statusIEIRI, Ichiro; KIMURA, Miyuki; IRIE, Shin et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 12, pp 851-859, issn 1744-6872, 9 p.Article